Skip to main content

Table 1 HLA class II phenotypes: MHC class II allele phenotyping for patients (L001–L006) who were vaccinated with p766 (DR1, 7, 15) and p672 (DR4, 11, 15) of hTERT.

From: Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs

Patient

HLA class II

L001

DRB1*04, DRB1*15;DQB1*0302/07/08/11, DQB1*06

L002

DRB1*04, DRB1*1302/31/34/36/39/41;DRB1*0302/07/08/11, DQB1*06

L003

DRB1*04, DRB1*07;DQB1*0301/09/10/13, DQB1*0303/06/12

L004

DRB1*08, DRB1*0301/15/16/28/35/40/51/53;DQB1*04, DQB1*06

L005

DRB1*03, DRB1*04, DQB1*02, DQB1*0301/09

L006

DRB1*15;DRB5*01;DQB1*06

  1. The alleles compatible with these peptides are in bold.
  2. HLA Class II testing was carried out by the National Blood Service Centre, Sheffield, UK. The method for HLA testing was through DNA analysis (Tepnel Lifecodes Luminex, UK).
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us